SCHEMBL7797950

SCHEMBL7797950

CCOc1cc(OC)c(C(=O)Nc2cccc3c2CCN(C)C3)cc1C#N

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
THRB P10828 1/20 0.44
MAP4K1 Q92918 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HSD17B10 Q99714 2/20 0.43
RXFP1 Q9HBX9 1/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPK1 P28482 2/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 1/20 0.42
MAP3K5 Q99683 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7791936 0.94 HSD17B10 (0.44) KDM4EALDH1A1MAPTTHRBMAP4K1
SCHEMBL7797922 0.93 KDM4E (0.46) KDM4EALDH1A1MAPTSMN1; SMN2HSD17B10
SCHEMBL7792101 0.92 ALDH1A1 (0.43) KDM4EALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL8183726 0.89 KMT2A (0.44) KDM4EALDH1A1MAP4K1SMN1; SMN2MEN1
SCHEMBL7797970 0.89 KMT2A (0.42) KDM4EMAPTMAP4K1SMN1; SMN2HSD17B10
SCHEMBL7799989 0.89 ALDH1A1 (0.44) KDM4EALDH1A1MAPTSMN1; SMN2HSD17B10
SCHEMBL7799980 0.88 HSD17B10 (0.43) KDM4EALDH1A1MAPTTHRBSMN1; SMN2
SCHEMBL7798022 0.88 HSD17B10 (0.43) KDM4EALDH1A1MAPTTHRBSMN1; SMN2
SCHEMBL7800095 0.87 MAP3K5 (0.45) KDM4EALDH1A1MAPTMAP4K1SMN1; SMN2
SCHEMBL7799945 0.87 KMT2A (0.46) KDM4EALDH1A1MAPTSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A KDM4E 910/4885ALDH1A1 494/4885MAPT 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.